Karin Hehenberger
Director/Board Member bei AADI BIOSCIENCE, INC.
Vermögen: 9 801 $ am 31.03.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Neil Desai | M | 59 |
Aadi Subsidiary, Inc.
Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | 13 Jahre |
Scott Giacobello | M | 54 | 3 Jahre | |
Anders Essen-Möller | M | 83 | 28 Jahre | |
Emma Reeve | F | 63 |
Aadi Subsidiary, Inc.
Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | 3 Jahre |
Ulf Hannelius | M | 49 | 8 Jahre | |
Behzad Aghazadeh | M | 52 |
Aadi Subsidiary, Inc.
Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | 3 Jahre |
Madiha Derouazi | M | 51 |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | 12 Jahre |
David Lennon | M | 53 | 1 Jahre | |
Richard E. Maroun | M | 69 |
Aadi Subsidiary, Inc.
Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | 7 Jahre |
Erik Kjellsson Nerpin | M | 63 | 12 Jahre | |
Anupam Dalal | M | 52 |
Aadi Subsidiary, Inc.
Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | 3 Jahre |
Marcy Graham | F | 57 | 2 Jahre | |
Caley Castelein | M | 53 | 3 Jahre | |
Martina Widman | F | 43 | 8 Jahre | |
Carl Torbjörn Bäckström | M | 76 | 7 Jahre | |
Markus Jerling | M | 72 | - | |
Mark Atkinson | M | 63 | 6 Jahre | |
Lars Lund | M | - |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | - |
Stephen M. Rodin | M | 47 | 2 Jahre | |
Mohammad Hirmand | M | 54 | 1 Jahre | |
Johan Dighed | M | 51 |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | - |
Karin Rosen | M | 57 | 1 Jahre | |
Bryan Ball | M | 54 | 2 Jahre | |
Loretta Itri | M | 74 | 3 Jahre | |
Andrew Kwon | M | - | 5 Jahre | |
Eva Karlström | F | 60 | 4 Jahre | |
Patrik Strömberg | M | - |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | 3 Jahre |
Charlotta Poehler | F | - |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | - |
Christoph Nowak | M | 38 | 3 Jahre | |
Karl Elmqvist | M | - |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | 2 Jahre |
Raymond Steitz | M | - | 2 Jahre | |
Berta Grigorian | F | - | 7 Jahre | |
George Avgerinos | M | 71 | 11 Jahre | |
Anton Lindqvist | M | 44 | 11 Jahre | |
John Öhd | M | 53 |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | - |
Zhen Yu Xiao | M | 50 |
Aadi Subsidiary, Inc.
Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | - |
Andreas Wallnöfer | M | 63 |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
Carlo Montagner | M | 56 |
Aadi Subsidiary, Inc.
Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | - |
Anna Styrud | F | 63 | 14 Jahre | |
Frank Kalkbrenner | M | - |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
Alan Henry Raffensperger | M | 64 |
Rolf Lufts Stiftelse Foer Diabetesforskning
| - |
Fredrik Lehmann | M | 48 |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | - |
Maria-Teresa Essen-Möller | F | 54 | 15 Jahre | |
Hans Johan Albert von Kantzow | M | 53 |
Rolf Lufts Stiftelse Foer Diabetesforskning
| - |
Mitchall G. Clark | M | 63 | 6 Jahre | |
Johanna Holldack | M | - |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | - |
David Lennon | M | - |
Aadi Subsidiary, Inc.
Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Brendan Delaney | M | 49 | 2 Jahre | |
Glenn L. Cooper | M | 71 | 4 Jahre | |
Bobby Sandage | M | 70 | 2 Jahre | |
Noah Beerman | M | 62 | 2 Jahre | |
Harlan Weisman | M | 71 | 1 Jahre | |
Dale Ritter | M | 73 | 2 Jahre | |
Xiao Qin Lu | M | 49 | 5 Jahre | |
Lance Thibault | M | 58 | - | |
Per Carendi | M | 76 |
Scandinavian Life Science Ventures AB
Scandinavian Life Science Ventures AB Investment ManagersFinance SLS Invest AB (SLS Invest) is a venture capital firm wholly-owned by Sjätte AP-fonden. The firm was established in 2007 and is headquartered in Stockholm, Sweden, with a branch office in Copenhagen, Denmark. | 4 Jahre |
Jonas Frick | M | 66 |
Scandinavian Life Science Ventures AB
Scandinavian Life Science Ventures AB Investment ManagersFinance SLS Invest AB (SLS Invest) is a venture capital firm wholly-owned by Sjätte AP-fonden. The firm was established in 2007 and is headquartered in Stockholm, Sweden, with a branch office in Copenhagen, Denmark. | - |
Karl Anders Falk | M | - |
Scandinavian Life Science Ventures AB
Scandinavian Life Science Ventures AB Investment ManagersFinance SLS Invest AB (SLS Invest) is a venture capital firm wholly-owned by Sjätte AP-fonden. The firm was established in 2007 and is headquartered in Stockholm, Sweden, with a branch office in Copenhagen, Denmark. | 5 Jahre |
Kevin J. Horgan | M | 64 | 1 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 30 | 50,85% |
Schweden | 12 | 20,34% |
Schweiz | 4 | 6,78% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Karin Hehenberger
- Persönliches Netzwerk